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Recurrent attacks of acute intermittent porphyria (AIP) result in poor quality of life and significant risks of morbidity and mortal-
ity. Liver transplantation (LT) offers a cure, but published data on outcomes after LT are limited. We assessed the pretransplant 
characteristics, complications, and outcomes for patients with AIP who received a transplant. Data were collected retrospectively 
from the European Liver Transplant Registry and from questionnaires sent to identified transplant and porphyria centers. We 
studied 38 patients who received transplants in 12 countries from 2002 to 2019. Median age at LT was 37 years (range, 18-58), 
and 34 (89%) of the patients were women. A total of 9 patients died during follow-up, and 2 patients were retransplanted. The 
1-year and 5-year overall survival rates were 92% and 82%, which are comparable with other metabolic diseases transplanted dur-
ing the same period. Advanced pretransplant neurological impairment was associated with increased mortality. The 5-year sur-
vival rate was 94% among 19 patients with moderate or no neuropathy at LT and 83% among 10 patients with severe neuropathy 
(P = 0.04). Pretransplant renal impairment was common. A total of 19 (51%) patients had a GFR < 60 mL/minute. Although 
few patients improved their renal function after LT, neurological impairments improved, and no worsening of neurological symp-
toms was recorded. No patient had AIP attacks after LT, except for a patient who received an auxiliary graft. LT is a curative treat-
ment option for patients with recurrent attacks of AIP. Severe neuropathy and impaired renal function are common and increase 
the risk for poor outcomes. If other treatment options fail, an evaluation for LT should be performed early.
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Acute intermittent porphyria (AIP) with recurrent 
attacks, defined as 4 or more attacks per year, is a rare con-
dition with severe morbidity and high mortality.(1,2) Liver 
transplantation (LT) offers a cure, but few centers are expe-
rienced, and limited data are available on the outcomes of 
patients and their porphyria-related comorbidities.
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AIP is a genetic disease caused by deficiency of the 
third enzyme in the heme biosynthetic pathway.(3) 
Typical symptoms are acute attacks that can include 
abdominal pain, hypertension, and gastrointestinal, 
neurological, and psychiatric symptoms. Most muta-
tion carriers have few attacks or are asymptomatic.(3-5) A 
minority of patients, approximately 5%,(1) who develop 
recurrent attacks of AIP are frequently hospitalized 
and have a poor quality of life.(2,6,7) Therapy includes 
symptomatic treatment and the infusion of exogenous 
heme during attacks to improve clinical symptoms 
and reduce mortality.(8) Preventive therapy with regu-
lar heme infusions is used to treat AIP with recurrent 
attacks despite disadvantages such as iron accumu-
lation and the risk of venous thrombophlebitis.(9,10) 
Gonadotropin-releasing hormone (GnRH) analogs 
are often tried in women with cyclical attacks.(11) 
Givosiran, a ribonucleic acid (RNA) interference ther-
apy, was recently approved for the treatment of AIP.(12) 
Givosiran may reduce the frequency of attacks in many 
patients, but long-term data are still limited. Patients 
with AIP are at risk for long-term complications, such 
as hypertension, renal impairment,(13) neuropathy,(14) 
and primary liver cancer.(15,16) Data on comorbidity 
and outcomes in patients with recurrent attacks of AIP 
are scarce. Renal impairment has been reported in up to 
64%(2,9) of patients with recurrent attacks. High rates 
of depression,(9) daily use of opioid pain treatment,(17) 
an increased risk of long-term sick leave, and the use 
of disability pensions(18) have also been reported. LT is 
currently the only curative treatment option.(19) Earlier 
published data are limited to a few case studies(19-22) 
and a case series on LT(23) and on combined liver- 
kidney transplantation.(24)
Based on more extensive experience than previously 
available, in this article we address several important 
issues regarding LT in AIP. What is the prognosis of 
AIP-associated renal and neurological complications 
after LT? Are there risk factors for poor outcomes? 
What disease-specific transplant complications need 
to be considered? Is hepatic artery thrombosis (HAT) 
frequent, as previously reported?(23) Timing of the 
decision to transplant is challenging. Patients have 
been reported to improve after years with regular 
heme infusions as a treatment for AIP with recur-
rent attacks,(9,17) but waiting too long for spontaneous 
improvement before considering LT increases the risk 
of complications such as renal impairment, iron accu-
mulation, progressive neurological impairment, and 
worse outcomes after LT.
With the aim to improve the understanding of these 
outstanding issues, we performed a retrospective cohort 
study based on questionnaires and registry data to assess 
the pre-LT characteristics, complications, and outcomes 
for patients in Europe who received an LT for AIP.
Patients and Methods
case iDentiFicatiOn anD 
stUDY inclUsiOn
Study inclusion criteria were diagnosis of AIP (an 
AIP diagnosis was confirmed by each reporting center 
based on local diagnostic guidelines) or the rarer forms 
of acute hepatic porphyria (AHP), variegate porphyria 
(VP), or hereditary coproporphyria (HCP) and a LT 
done in Europe. Patients were identified by searching 
the European Liver Transplant Registry (ELTR) data-
base, personal communications, and literature. Patients 
identified in the ELTR by a first or second diagnosis 
of “other porphyria” were excluded unless a definitive 
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AHP diagnosis could be confirmed by the identified 
transplant or porphyria center. (The ELTR list of dis-
ease codes include F9, protoporphyria [mainly eryth-
ropoietic protoporphyria], and F10, other porphyria.) 
Patients who were identified from the literature 
searches or personal communications were excluded 
if they could not be confirmed in the ELTR or if no 
questionnaire was obtained.
Except for a single patient with VP(21) who was not 
identified in the ELTR, no patients with the usually 
more benign forms of AHP, VP, or HCP were identi-
fied. This case was not included, and the study there-
fore focused only on AIP.
QUestiOnnaire
A questionnaire (case form) to collect basic informa-
tion was constructed and sent to identified centers 
that had managed the patients (Supporting File 1). 
Data were collected on baseline demographics, pre-
transplant morbidity, and perioperative and post-
operative complications and outcomes, including 
survival, retransplantation, neurological impairment, 
and renal impairment. Porphyria-related data were 
collected regarding pretransplant disease activity, 
disease duration, treatment, AIP mutation type, 
and porphyrin precursor excretion before and after 
transplantation. The questionnaire was designed to 
be concise and user friendly, mainly checkbox based 
with predetermined options, to enhance the response 
rate and reliability of the data and reduce issues of 
missing data. Some items were open to free-text 
comments, such as for pretransplant comorbidity 
(other than renal, neurologic, or hepatocellular car-
cinoma [HCC]) and for histology of the explanted 
liver.
cOMplicatiOns, renal anD 
neUrOlOgical iMpairMent
Peritransplantation and posttransplantation compli-
cations were graded using the Clavien-Dindo classi-
fication.(25) Complications were grouped into minor 
(grade I-II) and major (grade III-IV).
Renal function was assessed by glomerular fil-
tration rate (GFR): the latest recorded before LT, 1 
year after LT, and most recently recorded. If results 
from renal function tests (eg, iohexol plasma clear-
ance) were not available, GFR was estimated using 
the Cockcroft-Gault equation. Renal impairment 
was defined as chronic kidney disease (CKD) stage 
3 or higher (GFR  <  60  mL/minute). GFRs gener-
ally decrease after LT, especially during the first year, 
mainly a result of perioperative acute kidney injury and 
calcineurin inhibitors.(26) We defined stable GFR after 
LT as <30% decline from pre-LT GFR.
Neurological impairment was assessed by the report-
ing centers from medical records at the 3 time points: 
before, at, and after LT. The following 3 parameters 
were recorded: (1) motor function graded as normal 
function, impaired function, or paresis; (2) mobility 
graded as normal, walking with aid, wheelchair depen-
dent, or bedridden; and (3) neuropathic pain graded as 
none, moderate, or severe.
Overall survival, defined as the time from LT to 
death or last recorded observation, was compared 
with survival data from the ELTR for all patients 
who received transplants for other metabolic dis-
eases as well as for all patients who received trans-
plants during the ELTR collaboration from 2002 
to 2019.(27) (The ELTR metabolic diseases include 
Wilson’s disease [17%], hemochromatosis [8%], 
alpha-1-antitrypsin deficiency [10%], glycogen stor-
age disease [2%], homozygous hypercholesterol-
emia [<1%], tyrosinemia [2%], familial amyloidotic 
polyneuropathy [17%], primary hyperoxaluria [4%], 
protoporphyria [<1%], nonalcoholic steatohepatitis 
[10%], Crigler-Najjar syndrome [4%], cystic fibrosis 
[4%], Byler disease [3%], and other metabolic dis-
eases [21%]. Percentages are from the 2018 annual 
report of the ELTR.(26))
statistical analYsis
Stata special edition version 15:1 for Windows was 
used for all statistical analyses (StataCorp, College 
Station, TX). Descriptive study results are presented 
as percentages and medians and ranges. Survival 
analysis was done by the Kaplan-Meier curve method 
and log-rank test for equality of survivor functions. 
Comparisons of categorical variables were performed 
using the chi-square association test. For contin-
uous variables, 2-sample t-tests for the means was 
used. All P values <0.05 were considered statistically 
significant.
This study was approved by the institutional review 
board of the European Liver and Intestine Transplant 
Association.
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Results
patient cHaracteristics anD 
transplant inDicatiOns
We identified 42 patients with AIP in 13 European 
countries who received LTs from 2002 to 2019. 
Sufficient data for study inclusion were available for 38 
patients who received transplants at 21 centers in 12 
countries. Some patients were previously included in 
publications (Supporting File 2). ELTR data were avail-
able for 20 patients, and questionnaire data were avail-
able for 36 patients. Patient characteristics are presented 
in Table 1. The median age at LT was 37 years (range, 
18-58), and 34 patients (89%) were women. The most 
common transplant indication was frequent porphyria 
attacks (89%). A total of 2 female patients aged 48 
and 50 years at LT received transplants for HCC, both 
without cirrhosis. None of these patients had recurrent 
attacks of AIP in the year prior to LT. There were no 
reports of HCC recurrence at the latest follow-up. One 
patient had an urgent LT as a result of acute liver failure 
induced by an accidental heme overdose.(28)
pretransplant MOrBiDitY
The most common comorbidities were neuropa-
thy (68%) and renal impairment (51%) defined as a 
GFR < 60 mL/minute (CKD stage > 2). Some had 
complications to heme treatment in the form of central 
venous thrombosis (20%) or secondary hemochroma-
tosis (20%). Arterial hypertension, opioid dependency, 
recurrent infections, depression, and anxiety were the 
other reported comorbid conditions.
aip Disease
The median age at onset of AIP symptoms was 27 (range, 
16-44), and the median duration of active disease, de-
fined as the time from first documented AIP attack to 
LT, was 13 years (range, 3-35). Most patients (87%) had 
recurrent attacks of AIP, defined as 4 or more attacks per 
year, and 74% had >10 attacks annually. Most of the pa-
tients (94%) were treated with heme, and 29% had been 
treated with GnRH analogs. Mutation data were avail-
able for 17 patients who had 13 different mutations. The 
2 most common hydroxymethylbilane synthase (HMBS) 
mutations were W198X (593G  >  A; 17%, all from 
the Nordic countries) and R173W (517C > T; 17%). 
(W198X is also known as the Nordic founder muta-
tion; in this study, patients with this mutation were from 
Norway and Sweden.) Data on pretransplant urinary 
excretion of porphobilinogen and delta-aminolevulinic 
acid were reported for 18 patients. All of the patients 
had significantly elevated levels. Follow-up analyses 1 to 
3 days after LT showed normalized urinary excretion in 
all reported (n = 19) cases.
transplantatiOn
The median waitlist time was 30 weeks (range, 1 day to 
31 months). The median Model for End-Stage Liver 
Disease (MELD) score was 8 (range, 5-32), with most 
patients having low MELD scores (n = 27; median, 7; 
taBle 1. lt for aip from 2002 to 2019: patient 
characteristics (n = 38)
Female/male, n/n (%/%) 34/4 (89/11)
Age at LT, years, median (range) 37 (18-58)
Stated main indications for LT, n (%)
Frequent AIP attacks 33 (89)




Acute liver failure (accidental heme overdose) 1 (3)
Porphyria characteristics
Median age at onset of symptoms, years (range) 27 (16-44)
Median time from first porphyria symptom to LT, years 
(range)
13 (3-35)
Previous treatment, n (%)
Exogenous heme 32 (94)
GnRH analog 10 (29)




Comorbidities at time of LT, n (%)
Renal impairment, CKD stage > 2 (GFR < 60 mL/
minute)
19 (51)
Any neuropathy* 23 (68)
Central vein thrombosis 7 (20)
Type of transplantation, n (%)
Deceased donor 36 (97)
Living donor 1 (3)
Combined liver-kidney 5 (14)
Auxiliary 1 (3)
Time (weeks) on waiting list, median (range) 30 (0-135)
*Includes any paresis, impaired motor function, impaired mobility, 
or neuropathic pain at time of LT.
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range, 5-15). The higher MELD scores (range, 19-32) 
was reported in 6 patients were related to renal impair-
ment (n = 4), warfarin treatment (n = 1), and acute 
liver failure (n  =  1). A total of 7 centers in 5 coun-
tries used different forms of MELD exception systems 
that were applied to their 10 patients. Most (97%) re-
ceived grafts from deceased donors and 1 from a live 
donor. Of the patients, 5 (13%) received a combined 
liver-kidney transplant. One patient had an auxiliary 
transplant (ie, implantation of a partial donated liver 
without removing the native liver) and suffered con-
tinued AIP attacks after transplantation. Exogenous 
heme was administrated immediately before surgery in 
32% of the transplantations.
patient sUrvival
At the most recent follow-up, 29 patients (76%) were 
alive and 9 (24%) had died. The 1-year and 5-year 
overall patient survival rates were 92% and 82%, sim-
ilar to ELTR survival data on patients who received 
transplants for other metabolic diseases and all patients 
who received transplants from 2002 to 2019 (Fig. 1). 
Severe neurological impairment was associated with 
an increased mortality rate. Patients with any motor 
paresis or who were wheelchair dependent, bedridden, 
or suffered severe neuropathic pain at the time of LT 
(n = 10) had a 5-year survival rate of 83% compared 
with 94% in patients (n  =  19) with moderate or no 
neuropathy (P = 0.04) (Fig. 2A). Pretransplant renal 
impairment tended to increase mortality after LT. 
Patients with a GFR <60 mL at the pre-LT assessment 
(n = 14) who did not receive a combined liver-kidney 
transplant had a 5-year survival rate of 71% compared 
with 81% for patients (n = 18) with GFR > 60 mL/
minute (P = 0.16; Fig. 2B). All 5 patients who received 
combined liver-kidney transplants were alive at last 
follow-up. Two patients were retransplanted. The 




The rate of complications in the perioperative phase 
was low (9%). No complications were reported in 
39% of the patients who received transplants. Minor 
complications (Clavien-Dindo grade I-II), such 
as acute rejection, cytomegalovirus viremia, other 
infections, cholangitis, and deep venous thrombosis, 
were recorded in 26% of the patients who received 
transplants. Major complications (Clavien-Dindo 
grade III-IV), such as bile duct leakage or obstruc-
tion, wound tissue rupture, human herpes virus-6 
infection with multiorgan failure, and late bleeding 
requiring surgical intervention, were recorded in 
35%. Hepatic artery thrombosis (HAT) occurred in 
4 patients (11%), all women. One patient had early 
HAT within 1 month after LT, was retransplanted, 
and recovered. One patient (exact time for HAT 
missing) was retransplanted after 4.5  months but 
died 18  months later from cerebral hemorrhage. A 
third patient developed HAT after about 1 month 
and was listed for re-LT but deteriorated and died. 
A fourth patient developed HAT after 3 years and 
recovered without retransplantation.
neUrOlOgical iMpairMent
Almost all patients (93%) had paresis, impaired motor 
function, impaired mobility, or neuropathic pain be-
fore LT. Most improved after LT, and no patient ex-
perienced worsening of symptoms after LT. One third 
(33%) of the patients with moderate or severe neuro-
pathic pain had no motor or mobility impairment be-
fore LT. The frequencies of neurological impairment 
symptoms were lower in all 3 categories at follow-up 
Fig. 1. Kaplan-Meier curve plot of overall patient survival for the 
patients with AIP (n = 38), patients who received transplants for 
other metabolic diseases (n = 2941), and all patients who received 
transplants during the ELTR collaboration (n = 98,376) from 2002 
to 2019.
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after LT compared with the pre-LT assessments 
(Fig. 3A-C). Severe mobility impairment and paresis 
at LT and lower age at onset of symptomatic porphyria 
were associated with residual neuropathy after LT 
(Table 3).
renal iMpairMent
At pretransplant assessment, 4 patients (11%) had 
GFR  >90  mL/minute, 14 (38%) had a GFR 60 to 
90 mL/minute, 12 (32%) had a GFR 30 to 60 mL/minute, 
and 7 (19%) had a GFR  <30  mL/minute. Four of 
the patients with GFR  <30  mL/minute were on 
 hemodialysis or peritoneal dialysis and received 
combined liver-kidney transplantations. All pa-
tients had calcineurin inhibitor–based initial immune 
suppression: tacrolimus (n  =  36, 97%) and cyclo-
sporine (n  =  1, 3%). The median GFR before LT 
in patients who did not receive a combined liver- 
kidney transplant was 62  mL/minute, decreased to 
52  mL/minute at the 1-year follow-up, and was 
46 mL/minute at the most recent follow-up.
Post-LT GFR varied in patients with a pre-LT 
GFR  <  60  mL/minute who received only LT and 
had complete GFR information (n = 12). Although 
7 had stable GFR (defined as less than 30% decline 
from pre-LT GFR) or improved GFR, 5 had more 
than a 30% decline in GFR after LT (Fig.  4). All 
3 patients with CKD stage 4 (GFR < 30 mL/minute) 
at LT had a further worsening in renal function after 
LT with more than 30% decline in GFR at the lat-
est follow-up. The 5 patients who received combined 
liver-kidney transplantations were all alive with a 
median GFR of 63 mL/minute (range, 36-73) at lat-
est follow-up.
eXplanteD livers
Data were collected on 25 explanted livers (Table 4). 
The most common finding was increased iron deposits 
(72%), presumably from pre-LT heme therapy. Fibrosis 
stage 2 was found in 20%, only 1 (4%) had stage 3 fibro-
sis, and no liver was cirrhotic (stage 4). The explanted 
livers from the 2 patients who received transplants for 
HCC showed no advanced fibrosis or cirrhosis. HCC 
was not found in any other explanted livers.
Discussion
In this largest case series to date, we report on the char-
acteristics and outcomes of 38 LTs done for AIP in 12 
European countries from 2002 to 2019. We confirm 
that LT is a curative option for patients with severe 
AIP with recurrent attacks. Survival rates are compara-
ble to similar transplant indications. Neurological im-
pairment improves after transplantation, whereas renal 
impairment in most patients does not. At least 3 of 
the women in this study gave birth to healthy children 
after LT.
AIP is a rare disease, and only a small fraction 
of symptomatic patients develop recurrent attacks 
(4 or more attacks per year). These patients, mostly 
women in their 20s and 30s, suffer repeated painful 
attacks; poor quality of life; frequent hospitalizations; 
temporary or progressive neurological impairment; 
vascular, renal, and psychiatric comorbidity; and a 
Fig. 2. (A) Kaplan-Meier curve plots of overall survival for 
patients with severe neuropathy (any motor paresis, wheelchair 
dependent, bedridden, or severe neuropathic pain; n  =  10) and 
moderate or no neuropathy at LT (n = 19; P = 0.04). (B) Kaplan-
Meier curve plots of overall survival for patients receiving only LT 
with GFR > 60 mL/minute (n = 18) and GFR < 60 mL/minute 
(n = 14) pre-LT (P = 0.16).
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high mortality risk. The economic burden on the 
health care systems is substantial.(2) Medical treat-
ment options have been limited. Since the first 
report on LT for AIP in 2004,(19) this option has 
become an established rescue therapy even if pub-
lished data have been limited. The aim of this study 
was to assemble and offer comprehensive data to aid 
clinicians when LT is considered for severe AIP with 
recurrent attacks.
The 1-year and 5-year survival rates of 92% and 
82%, respectively, are comparable with patients who 
received transplants for other metabolic diseases and 
with all patients who received transplants during the 
same time period (Fig. 1). Compared with other LT 
indications, the median age of 37 in this cohort is, 
however, low, and higher survival rates would be desir-
able. The identification of risk factors for worse out-
comes after LT is of value to support optimal selection 
and timing. We found that most patients had a long 
duration of AIP before LT was done, 13 years on aver-
age, and that the majority of patients had developed 
AIP-related comorbidities. This suggests that LT gen-
erally is considered late in the disease course and high-
lights the importance of the assessment for LT before 
comorbid conditions become too advanced. Severe 
neuropathy at LT was associated with an increased risk 
of mortality.
Among the patients who died, we identified the fol-
lowing 3 factors that deserve attention:
1. At least 2 patients were in poor clinical condition 
at the time of LT, and 1 patient was ventilator 
dependent as a result of AIP neuropathy. Generally, 
LT should, when possible, be considered earlier 
in the disease course.
2. An earlier case series(23) reported HAT in 40% 
of AIP LT recipients. We identified 4 patients 
(11%) with HAT in this study, which led to re-
transplantation in 2 patients and death in 1 pa-
tient. The HAT rate of 11% is low compared with 
the previously reported 40% but higher than an 
expected rate of 3% to 9% in general LT.(29) Two 
of the previously reported cases of HAT(23) are, 
however, not included in this study as a result of 
nonresponse from the transplant center, suggest-
ing a real HAT rate of more than 11%. The oc-
currence of both early and very late HAT suggests 
that the cause or causes may not be AIP related. 
Some of the previously described risk factors for 
early HAT are low recipient age, low recipient 
weight, metabolic disease, and female sex.(30,31) 
These factors apply to the patients in this AIP 
cohort. Based on the limited data presented here 
and previously, an individual assessment of throm-
boembolic risk and close monitoring after LT is 
recommended for patients with AIP who receive 
transplants. Anticoagulant prophylaxis should be 
considered based on individual risk factors.
3. Renal dysfunction was linked to several deaths, 
both early and late after LT. Data on the outcome 
of renal impairment after LT for AIP have been 
scarce. Half of the patients in this cohort (50%) 
had CKD stage 3 or worse at LT. The trends in 
GFR after LT varied considerably between pa-
tients. The median GFR was 62  mL/minute at 
pre-LT assessment, 52  mL/minute 1-year post 
LT, and 46 mL/minute at last follow-up. A pro-
gressive decline in GFR, particularly in the first 
year after LT, is not uncommon, and post-LT 
taBle 2. causes of Death
Case No. Time From LT Background Cause of Death
1 3 months Ventilator dependent for months before LT; GFR 
34 mL/minute
Sepsis and multiorgan failure
2 4 months No data No data
3 7 months “Very poor vascular condition” before LT; GFR 45 mL/
minute before LT
Pulmonary infection
4 2 years Hepatic artery thrombosis, retransplantation, died 
from cerebral hemorrhage
5 3 years Hepatic artery thrombosis
6 3 years Auxiliary LT Recurrent AIP attacks, cardiac and renal impairment 
after LT
7 5 years Patient ended immunosuppression therapy
8 8 years GFR 54 mL/minute before LT Sepsis, renal failure
9 8 years GFR 28 mL/minute before LT Complications from chronic renal failure
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Fig. 3. Rates (percentages) of 3 categories of neuropathic symptoms before LT at the time of transplantation and at latest recorded 
follow-up. Numbers are patients with sufficient data to be included in the analysis: (A) motor neuropathy (n = 29), (B) impaired mobility 
(n = 28), and (C) neuropathic pain (n = 24).
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renal impairment is an independent risk factor for 
morbidity and mortality.(26,32) Almost half of the 
patients with a pre-LT GFR < 60 mL/minute but 
no patients with GFR < 30 mL/minute who re-
ceived only LT had stable or improved GFR after 
transplantation. A minority of patients with im-
paired renal function at LT improved their GFR 
after LT. AIP-related renal impairment appears 
to have multifactorial causes(33,34) and may in 
some be reversible with LT (Fig. 4). All 5 patients 
who received a combined liver-kidney transplant 
in this study were alive with preserved renal func-
tion. Hence, progressive renal impairment in a 
patient with severe AIP with recurrent attacks is a 
finding that should hasten decisions on the evalu-
ation for LT. In patients approaching severely 
impaired renal function (GFR < 30 mL/minute), 
a combined liver-kidney transplant should be 
thoroughly considered because expected further 
decline in renal function following LT imposes 
a significant risk of the patient deteriorating to 
end-stage renal disease.
taBle 3. pretransplantation clinical Features associated With persistent neuropathy after lt
Variable n Persistent Neuropathy Neuropathy Absent Difference Chi-Square Test P Value
Age at onset of AIP (n), 
mean years
21 (7) 23 (14) 33 9.4 — 0.01
Time from onset of AIP to 
LT (n), mean years
23 (7) 16 (15) 10 5.5 — 0.10
Severe paresis at LT, n (%) 5 4 (80) 1 (20) — 5.5 0.02
Moderate/no paresis at 
LT, n (%)
24 6 (25) 18 (75)
Severe mobility impair-
ment at LT, n (%)
4 3 (75) 1 (25) — 3.9 0.05
Moderate or no mobility 
impairment at LT, n (%)
24 6 (25) 18 (75)
NOTE: Persistent neuropathy includes any residual motor neuropathy, mobility impairment, or neuropathic pain at last assessment after 
LT. Age at LT and time from onset of AIP to LT was compared by a 2-sample t test for the means. Grade of paresis and mobility impair-
ment at LT was compared by chi-square association test.
Fig. 4. Percent change in GFR from before to most recent value after LT for 12 patients with pretransplant GFR 30 to 60 mL/minute 
(black bars, n = 9) or <30 mL/minute (gray bars, n = 3).
taBle 4. liver Histology: explanted livers (n = 25)
Histopathology n %
Increased iron deposits 18 72
Fibrosis stage* 0-1 17 67
Fibrosis stage 2 5 20
Fibrosis stage 3 1 4
Cirrhosis stage 4 0 0
HCC, no cirrhosis 2 8
*Fibrosis stages according to the metavir staging system.
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Neurological impairment is frequent in AIP with 
recurrent attacks(14) and was a common contributing 
factor for transplant referral. Most patients improved, 
and no patients progressed in neurological impairment 
after LT. The rates of patients with paresis or impaired 
motor function, impaired mobility, or neuropathic pain 
were lower after LT (Fig. 3A-C). Severe motor neu-
ropathy at LT, often in combination with lower age at 
onset of symptomatic AIP, was associated with an in-
creased risk of residual neuropathy after LT.
Patients with AIP have an increased risk of devel-
oping primary liver cancer, most commonly HCC 
but also, less frequently, cholangiocarcinoma or 
mixed forms.(15,16) Most non-AIP HCC occur in 
male patients with cirrhotic liver disease. In contrast, 
most AIP-related primary liver cancers are diag-
nosed in females without significant fibrosis.(35) In 
the 2 female patients with HCC in this study, aged 
48 and 50 at LT, liver histology showed no advanced 
fibrosis or cirrhosis. Histology reports on explanted 
livers were available from a total of 25 patients in 
this study. In line with previous observations,(22) few 
significant histopathological findings were reported 
except for mild to moderate fibrosis and iron accu-
mulation that was presumably caused by pre-LT 
heme treatment.
A novel RNA interference therapy, givosiran, 
was recently approved by the European Medicines 
Agency and US Food and Drug Administration for 
the treatment of AIP.(12) Givosiran may reduce the 
frequency of attacks in many patients, but LT will 
remain an option when this and other treatment 
options are ineffective.
Based on these and previous results, we recommend 
that the evaluation for LT should be considered at 
an early stage in all patients with AIP suffering from 
recurrent attacks with insufficient responses to available 
therapies. The evaluation should include the careful 
assessment of several interacting factors such as fre-
quency and severity of attacks; response, tolerance, and 
adherence to treatments; severity and disease course of 
comorbidities, particularly renal and neurological; age; 
and, not least, the patient’s quality of life. An LT unit, 
preferably with experience in AIP, should be involved 
in the evaluation. Combined liver-kidney transplanta-
tion should be considered if renal impairment is severe 
(CKD stage >3) or progressive.
The strengths of this study include the large number 
of cases (in an AIP context) and up to 16 years of clinical 
follow-up and registry data that may provide support 
in the often difficult decision about if and when to 
consider LT in AIP. This study has several limitations. 
Retrospective registry and questionnaire data based 
on medical records should be interpreted with caution 
considering the risk of information bias. The ques-
tionnaires that were sent to the identified transplant 
and porphyria centers were intentionally designed to 
encourage high compliance and response rates and 
reduce issues of missing data. Accordingly, the amount 
and level of detail in the collected data were less than 
what would be desirable. Data were not available for 
4 (10%) patients who received transplants. Of these, 
2 patients had HAT, as commented previously, and 
the data from these might have added valuable infor-
mation on this rare complication. Information about 
neurological impairment was collected from patients’ 
medical records. The simple scales for grading impair-
ment offer little information about time lag between 
LT and improvement or about symptom details.
In conclusion, this study confirms that LT offers 
a cure from AIP symptoms with good survival rates. 
Porphyria-related neuropathy improves, but severe 
neuropathy and advanced pretransplant renal impair-
ment increase the risk of poor outcomes. Patients with 
AIP with recurrent attacks and signs of renal impair-
ment and/or severe neuropathy who do not respond to 
other therapeutic options should therefore be consid-
ered for LT, and a transplant center should be involved 
in the discussion at an early stage, before AIP-related 
comorbidity is complex or severe.
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